-
UNPARALLELED SCALABILITY
10x increase in productivity compared with conventional CDMOs
-
COST SAVINGS
50% lower price per batch compared with conventional CDMOs
-
QUALITY
75% lower process failure rates compared with conventional CDMOs
-
Smart Factory
South San Francisco, CA - Preclinical & Clinical Services / Technology Development
- 57,000 Sq Ft
-
Smart Factory
South San Francisco, CA - Preclinical & Clinical Services / Technology Development
- 57,000 Sq Ft
-
Smart Factory
Bridgewater, NJ - Preclinical, Clinical & Commercial Services
- 118,000 Sq Ft
-
Smart Factory
Bridgewater, NJ - Preclinical, Clinical & Commercial Services
- 118,000 Sq Ft
-
Smart Factory - Europe
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Europe
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Asia
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Asia
COMING SOON - Preclinical, Clinical & Commercial Services
- Existing Smart Factories
- Planned Smart Factories
- Manufacturing Services
-
- Advanced Technology
-
Scalability
10x increase in productivity
-
Cost Savings
50% reduction in cost per batch
-
QUALITY
Reduction in process failure rates
-
FLEXIBILITY
Majority of cell therapy modalities supported
Careers
Do What’s Never Been Done Before
Cellares is always looking for passionate and world-class professionals to join our interdisciplinary team
-
April 22, 2024
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
-
April 18, 2024
Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies, to Resolve Manual QC Processing Bottleneck and Extend IDMO Capabilities from Manufacturing Through Quality Control
-
March 26, 2024
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing